PUBLISHER: Polaris Market Research | PRODUCT CODE: 1424032
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1424032
The global lipid regulators market size is expected to reach USD 11.75 billion by 2032, according to a new study by Polaris Market Research. The report "Lipid Regulators Market Share, Size, Trends, Industry Analysis Report, By Type (Statins, Non-statins); By Product; By Phase; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Lipids are fatty compounds with predetermined functions in the human body. They are known to be insoluble in water (polar solvents) and soluble in organic solvents. The inconsistent levels of lipids in the body can lead to coronary artery diseases, cardiovascular diseases, pancreatitis, and more. This is driving the need for lipid regulators, which can regulate lipids, specifically cholesterol and triglycerides. With the potential to lower production or eliminate the lipids in the human body, they are highly anticipated for adoption in the pharmaceutical space in the foreseeable future. For instance, a 2023 study published in MDPI focused on exploring the effectiveness and risks of lipid-lowering drugs in pharmacotherapy.
Researchers are working enormously to reveal the potential lipid regulators to develop efficient treatments for various diseases with a view to enhancing the lives of people around the world. In a 2023 study on the drug screening process of macrophage foam cells, verteporfin was identified as a regulator of lipid metabolism and inflammation and suggested significant potential in treating atherosclerosis. This supports lipid regulator market growth as it can be employed in the treatment of atherosclerosis, facilitating significant demand in the marketplace.
Lipid regulators are prominent in treating dyslipidemias, mainly in controlling increased cholesterol levels in the blood. The increased cholesterol levels are the major factor that causes atherosclerosis, leading to increased levels of deaths due to cardiovascular diseases in the UK. The rising cases of these diseases are likely to support lipid regulator market growth in the long run.
The ongoing studies focusing on the real-time work of lipid regulators in certain species are encountering new potential opportunities for lipid regulators in the marketplace. A study published in 2023 conducted a review of the health effects of lipid regulators, statins, and fibrates among finfish species.
Statins segment is anticipated to witness the highest growth in the coming years due to its potential to lower cholesterol.
Cholesterol segment accounted for the largest market share owing to the rising health issues associated with higher cholesterol levels.
Clinical segment is projected to experience a larger revenue share due to the rising innovation of new drugs in dealing with lipid regulation.
Asia Pacific is projected to register the fastest growth during the forecast period, attributable to the presence of the elderly population.
The global players include AbbVie Inc, Amgen, Andrx Corporation, AstraZeneca, Bristol-Myers Squibb, Merck KGaA, Novartis, Pfizer, and Teva Pharmaceuticals.
Polaris Market Research has segmented the lipid regulators market report based on type, product, phase, and region: